Beijing Super Vision Technology was co-founded by Professor Wang Lejin, Department of Ophthalmology, Peking University People’s Hospital, and several professors from the Department of Precision Instruments, Tsinghua University, Beijing University of Technology, School of Microelectronics, and Institute of Physics and Chemistry, Chinese Academy of Sciences. It is committed to solving difficult human eye diseases and improving the quality of life of patients with eye diseases. A high-tech R&D enterprise with completely independent intellectual property rights and R&D and production capabilities.

The company has successively completed three rounds of equity financing invested by well-known institutions such as Shuimu Venture Capital, Peking University Medical Industry Fund, China Development Leadership Fund and Dongsheng Expo Technology Development Co., Ltd. under the Industrial Development Research Institute of Tsinghua University, with a total amount of 60 million yuan. Yuan.

The companys core product "Eye Muscle Nerve Stimulator" is the worlds first high-end medical device. This product is used to treat congenital nystagmus, a world problem called "incurable disease" in ophthalmology. The project has won the global championship of the 2020 "Dongsheng Cup" Innovation and Entrepreneurship Competition and the first prize of the China Medical Device Innovation and Entrepreneurship Competition and other honors and widespread social recognition. The company also has products for the treatment of high myopia, strabismus and glaucoma in the development process.